CHRONULAC
LOE ApproachingNDAORALSOLUTION
Approved
Jun 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHRONULAC is an oral solution small-molecule drug approved in 1979 by Sanofi. The specific indication and mechanism of action are not documented in available data, limiting clinical context. This long-established product represents a legacy franchise requiring maintenance-focused commercial strategy.
LOE Approaching
As LOE approaches, brand teams are likely shifting from growth investment to defensive strategy and cost optimization; headcount stability or modest reductions expected.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHRONULAC careers are now primarily in defensive commercial roles rather than growth-oriented positions. This is a stability-focused environment with limited advancement opportunity; consider this role a base for portfolio exposure or as a consolidation position before transitioning to growth-stage assets.
Brand ManagerField Sales Representative
Worked on CHRONULAC at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.